Lidocaine (IV - prokinetic)

Lidocaine, while primarily recognized as a local anesthetic agent, has emerged as one of the most important prokinetic medications in equine surgical practice when administered as a continuous intravenous infusion. The discovery of lidocaine's beneficial effects on gastrointestinal motility and its anti-inflammatory properties has made it a cornerstone of post-operative management for horses undergoing colic surgery. Unlike lidocaine's well-understood local anesthetic mechanism, the exact pathways by which it enhances gut motility remain the subject of ongoing research, though the clinical benefits have been consistently demonstrated in equine patients.

The mechanisms by which lidocaine enhances gastrointestinal motility are multifactorial and not completely elucidated. At the systemic concentrations achieved during intravenous infusion, lidocaine appears to reduce intestinal inflammation and sympathetic nervous system activation that contribute to post-operative ileus. The medication may directly affect smooth muscle function and enteric nervous system activity. Anti-inflammatory effects help modulate the intestinal inflammatory response that follows surgical manipulation and ischemia-reperfusion injury. Lidocaine also provides systemic analgesia that may indirectly support motility by reducing pain-induced sympathetic inhibition of gut function. This multifaceted mechanism distinguishes lidocaine from other prokinetic agents with more specific receptor-mediated effects.

Lidocaine for prokinetic use is administered exclusively through intravenous constant rate infusion, typically using calibrated infusion pumps that deliver a precise, continuous dose over an extended period. Treatment commonly begins during or immediately after surgery and continues for twenty-four to seventy-two hours or longer depending on clinical response. The medication is usually delivered through an intravenous catheter in a jugular vein, often incorporated into the horse's fluid therapy regimen. The constant infusion approach maintains steady plasma concentrations that provide sustained effects on the gastrointestinal tract while avoiding the toxic peak levels that would occur with intermittent bolus dosing.

The safety profile of lidocaine infusion in horses is favorable when proper dosing and monitoring protocols are followed, though the medication has a relatively narrow therapeutic index requiring attention to plasma concentrations. Signs of lidocaine toxicity are typically neurological, progressing from muscle fasciculations to ataxia and potentially seizures at very high levels. These effects are dose-dependent and reversible upon reducing or discontinuing the infusion. Continuous monitoring during lidocaine infusion is essential, particularly in the initial hours and in horses with conditions that might alter drug metabolism or distribution. The benefits of lidocaine therapy in appropriate surgical patients generally outweigh risks when treatment is administered under proper veterinary supervision.

The primary indication for intravenous lidocaine infusion in horses is the prevention and treatment of post-operative ileus following abdominal surgery for colic. Post-operative ileus represents one of the most significant complications of equine colic surgery, occurring when normal gastrointestinal motility fails to return following surgical manipulation of the intestines, general anesthesia, and the systemic inflammatory response to abdominal disease. Ileus prolongs hospitalization, increases the risk of adhesion formation, promotes fluid accumulation requiring nasogastric decompression, and in severe cases may necessitate additional surgery or prove fatal. Lidocaine infusion has become standard of care at many equine referral centers for managing surgical colic patients.

Beyond post-operative ileus specifically, lidocaine infusion provides benefits in the broader context of post-surgical colic management. The medication's anti-inflammatory effects help modulate the intestinal inflammatory response that follows ischemia-reperfusion injury, a common consequence of conditions such as strangulating obstructions and volvulus. By reducing inflammation within the intestinal wall, lidocaine may help preserve intestinal viability and function. The analgesic properties of systemic lidocaine contribute to patient comfort during recovery, potentially reducing the need for other analgesic medications that might have more negative effects on gastrointestinal motility.

Severe gastrointestinal hypomotility from non-surgical causes may also be treated with lidocaine infusion in some cases. Horses experiencing profound ileus secondary to conditions such as anterior enteritis, peritonitis, or severe systemic illness may benefit from lidocaine therapy as part of comprehensive medical management. In these situations, lidocaine is typically used alongside other supportive treatments including intravenous fluids, electrolyte correction, and management of the underlying condition. The decision to use lidocaine in non-surgical cases depends on the severity of ileus and the clinical judgment of the attending veterinarian.

Lidocaine infusion may provide benefit in managing intestinal inflammation and dysfunction associated with conditions beyond classic post-operative ileus. Inflammatory bowel conditions, endotoxemia with secondary gastrointestinal effects, and complicated impactions with intestinal wall compromise may show improved outcomes with lidocaine therapy. Research continues to explore additional applications for lidocaine infusion in equine gastrointestinal disease, with some studies suggesting benefits in specific clinical scenarios. The versatility of lidocaine's effects on inflammation, motility, and analgesia makes it a valuable tool across a range of gastrointestinal conditions.

The selection of lidocaine infusion for a particular patient depends on the clinical situation, available monitoring capabilities, and overall treatment plan. Lidocaine is typically used in referral hospital settings where constant rate infusion and continuous patient monitoring are feasible. The medication is usually not appropriate for outpatient or field treatment of motility disorders due to the requirement for intravenous infusion and the need for toxicity monitoring. Lidocaine may be used in combination with other prokinetic agents that work through different mechanisms, providing complementary effects through multiple pathways to maximize return of normal gut function.

Lidocaine dosing for prokinetic and anti-inflammatory effects in horses follows established protocols that have been refined through clinical experience and research, though the attending veterinarian determines the specific regimen for each patient. The medication is administered as a constant rate intravenous infusion, requiring accurate calculation of flow rates and use of appropriate delivery equipment. Most protocols begin with a loading dose followed by a maintenance infusion at a lower rate. Accurate patient weight is essential for proper dosing, as lidocaine's therapeutic window is relatively narrow and toxicity is dose-dependent.

Typical lidocaine infusion protocols begin with a loading dose of 1.3 milligrams per kilogram of body weight administered intravenously over fifteen to twenty minutes. This loading dose helps achieve therapeutic plasma concentrations more rapidly than would occur with maintenance infusion alone. Following the loading dose, maintenance infusion typically proceeds at 0.05 milligrams per kilogram per minute, which can also be expressed as 3 milligrams per kilogram per hour. Some protocols use slightly different rates, and the veterinarian may adjust the infusion rate based on clinical response and any signs of toxicity. The concentration of lidocaine solution and the calculated flow rate must be precisely determined to deliver the intended dose.

Treatment duration with lidocaine infusion varies depending on clinical response and the nature of the underlying condition. For post-operative ileus following colic surgery, infusion commonly continues for twenty-four to seventy-two hours, with duration guided by evidence of return of normal gastrointestinal function. Signs indicating successful treatment include passage of manure, reduced nasogastric reflux volume, return of audible borborygmi, and improved appetite. Some horses require longer infusion periods, particularly those with severe intestinal compromise or slow return of motility. The infusion may be discontinued abruptly when no longer needed, or tapered in some protocols.

Administration of lidocaine infusion requires appropriate equipment and monitoring capabilities. Calibrated fluid infusion pumps provide the most accurate and consistent delivery, particularly for the relatively low flow rates required for lidocaine. The medication is typically added to a bag of intravenous fluids at a calculated concentration, and the pump is set to deliver the appropriate volume per hour. For a 500 kilogram horse receiving 0.05 milligrams per kilogram per minute, this equals 25 milligrams per minute or 1,500 milligrams per hour. Common preparations place 500 to 2,000 milligrams of lidocaine in a one-liter bag of fluids and adjust the flow rate accordingly. Careful labeling and documentation of concentrations and rates is essential.

Missed doses are not a typical concern with constant rate infusions, as the goal is continuous uninterrupted delivery. If an infusion is inadvertently interrupted, the veterinarian will determine whether to simply resume the infusion or whether an additional loading dose is warranted. Extended interruption allows plasma lidocaine concentrations to decline, potentially losing therapeutic benefit. Conversely, accidental increases in infusion rate could rapidly elevate concentrations to toxic levels, emphasizing the importance of proper pump programming and monitoring.

Discontinuation of lidocaine infusion is determined by the attending veterinarian based on clinical assessment. When gastrointestinal function has adequately returned and the horse is progressing well, the infusion can typically be stopped without tapering. There is no rebound phenomenon or withdrawal concern with lidocaine discontinuation. If signs of ileus recur after discontinuation, resuming the infusion may be considered based on the clinical situation.

Lidocaine infusion is generally well-tolerated in horses when administered at appropriate rates with proper monitoring, though the medication does have the potential for significant toxicity if plasma concentrations exceed the therapeutic range. Understanding the signs of lidocaine toxicity allows early recognition and intervention before serious adverse effects occur. The effects of lidocaine toxicity are dose-dependent and typically reversible upon reducing or discontinuing the infusion. Continuous observation of horses receiving lidocaine is an essential component of safe therapy.

Mild effects that may be observed even at therapeutic lidocaine concentrations include subtle changes in mentation such as mild sedation or altered awareness. Some horses may appear quieter or more subdued than their baseline demeanor. Mild muscle fasciculations, particularly visible over the shoulders and hindquarters, may be noted and do not necessarily indicate toxicity if subtle and not progressing. These mild effects often do not require intervention but warrant continued close monitoring. Any progression or worsening of these signs should prompt reassessment of the infusion rate.

Moderate side effects indicating potentially elevated lidocaine concentrations include more pronounced muscle fasciculations, particularly if widespread or persistent. Ataxia or incoordination when the horse moves suggests significant central nervous system effects. Behavioral changes such as restlessness, anxiety, or depression may be observed. Increased heart rate or changes in heart rhythm can occur at elevated concentrations. These signs warrant reducing the infusion rate and closely observing for improvement versus progression. The veterinarian should be informed of any moderate toxicity signs so that appropriate adjustments can be made.

Serious side effects of lidocaine toxicity require immediate intervention. Severe ataxia or recumbency indicates dangerously elevated plasma concentrations. Seizure activity represents serious toxicity demanding immediate cessation of the infusion and potentially anticonvulsant therapy. Cardiovascular collapse with hypotension and cardiovascular depression can occur at very high concentrations. Respiratory depression is possible at toxic levels. These severe effects should prompt immediate discontinuation of the lidocaine infusion and supportive care as indicated. Having emergency drugs available, including diazepam or other anticonvulsants, is advisable when administering lidocaine infusions.

Rare effects and special considerations include potential cardiac arrhythmias in horses with pre-existing cardiac conditions. Horses with hepatic dysfunction may metabolize lidocaine more slowly, leading to accumulation even at standard infusion rates. Debilitated or critically ill horses may be more susceptible to lidocaine toxicity. The concurrent use of other drugs that affect lidocaine metabolism can alter plasma concentrations. Some individual horses appear more sensitive to lidocaine effects than others, emphasizing the importance of monitoring each patient rather than relying solely on calculated doses.

Lidocaine infusion is contraindicated in horses with known hypersensitivity to lidocaine or other amide-type local anesthetics. Previous allergic reactions to lidocaine, mepivacaine, bupivacaine, or related drugs should preclude use. While true allergic reactions to lidocaine are rare, they can occur and may manifest as anaphylaxis or less severe hypersensitivity reactions. Any history of adverse reactions to local anesthetics should be disclosed to the veterinarian when considering lidocaine therapy.

Horses with significant cardiac conduction abnormalities represent a population requiring careful consideration before lidocaine infusion. While lidocaine is actually used as an antiarrhythmic agent in some contexts, it can also cause or worsen certain arrhythmias depending on the underlying condition. Horses with pre-existing heart block, severe bradycardia, or other significant conduction abnormalities should undergo cardiac evaluation before lidocaine infusion. In some cases, the risks may outweigh benefits, while in others, treatment may proceed with enhanced cardiac monitoring. The veterinarian will assess each case individually.

Severe hepatic dysfunction contraindicates standard lidocaine infusion protocols due to impaired drug metabolism. Lidocaine undergoes hepatic metabolism, and horses with liver disease may accumulate the drug to toxic concentrations even at normally safe infusion rates. If lidocaine use is considered essential in a horse with hepatic compromise, significantly reduced infusion rates and intensive monitoring would be necessary. Measurement of plasma lidocaine concentrations, where available, may help guide therapy in these patients. Alternative prokinetic agents without hepatic metabolism requirements may be preferred.

Hypovolemia and shock states require correction before or concurrent with lidocaine infusion. Lidocaine's cardiovascular effects may be exaggerated in hypovolemic patients, potentially contributing to hypotension. Horses presenting for colic surgery may be significantly dehydrated and require aggressive fluid resuscitation as part of their treatment. The loading dose of lidocaine may be modified or delayed until cardiovascular status is stabilized. Ongoing fluid therapy during lidocaine infusion helps maintain adequate circulating volume and drug distribution.

Special considerations apply to pregnant mares, though colic requiring surgery during pregnancy creates a situation where the benefits of lidocaine for post-operative management likely outweigh risks. Lidocaine crosses the placenta and could affect the fetus, but this consideration must be balanced against the critical importance of maternal recovery from abdominal surgery. Nursing mares receiving lidocaine present questions about drug excretion in milk, though the clinical significance during short-term post-operative infusion is uncertain. Very young foals may have different pharmacokinetics for lidocaine, though this population rarely requires prokinetic therapy with this agent.

Lidocaine has potential interactions with several drug classes commonly used in equine surgical and critical care settings. Other antiarrhythmic medications may have additive effects on cardiac conduction when combined with lidocaine. While lidocaine itself has antiarrhythmic properties, combining it with other drugs affecting the cardiac conduction system increases the complexity of cardiovascular management. Beta-adrenergic blockers, calcium channel blockers, and other cardiac medications require consideration when planning lidocaine infusion. The veterinarian will assess the overall medication profile and adjust monitoring accordingly.

Drugs that inhibit hepatic cytochrome P450 enzymes may impair lidocaine metabolism, potentially leading to accumulation and increased toxicity risk. While this interaction is more commonly discussed in human medicine with specific medications, the principle applies in veterinary practice as well. Cimetidine, while not commonly used in horses, is one example of a drug that can inhibit lidocaine metabolism. Any medications known to affect hepatic enzyme function should be considered when planning lidocaine therapy.

Lidocaine has both additive and potentially beneficial interactions with various analgesic medications. The systemic analgesic effects of lidocaine infusion may reduce requirements for other pain medications in post-operative horses. Combining lidocaine with opioids, alpha-2 agonists, or other analgesics should account for potential additive sedative or cardiovascular effects. Non-steroidal anti-inflammatory drugs are commonly used alongside lidocaine in post-operative colic patients, and this combination is generally considered safe and complementary. The overall analgesic plan should be coordinated to provide adequate pain control while minimizing cumulative side effects.

Other prokinetic medications may be used in combination with lidocaine when multi-agent therapy is warranted for severe post-operative ileus. Metoclopramide, bethanechol, erythromycin, and other prokinetics work through different mechanisms than lidocaine, potentially providing additive or synergistic effects. Such combinations should be used with veterinary oversight, as increased gut stimulation could theoretically cause cramping or other effects. However, in practice, combination prokinetic therapy is commonly employed in refractory cases with acceptable safety profiles.

Competition drug considerations for lidocaine are significant. Lidocaine is a prohibited substance under FEI rules and most other competitive governing body regulations due to its analgesic and other pharmacological properties. Detection times following intravenous infusion may be prolonged. Horses receiving lidocaine therapy, typically for serious medical conditions requiring hospitalization, should not be expected to compete until an extended period after treatment, with specific withdrawal times determined by current regulations and veterinary guidance.

Monitoring during lidocaine infusion is essential for safe therapy and represents a fundamental component of treatment protocols. Continuous or very frequent observation allows early detection of toxicity signs before they progress to dangerous levels. Monitoring parameters include mentation and behavior, watching for changes from baseline that might indicate central nervous system effects. Observation for muscle fasciculations should be ongoing, as these may be early indicators of elevated plasma concentrations. Cardiovascular monitoring including heart rate and rhythm assessment helps identify cardiac effects. The infusion site and equipment should be checked regularly to ensure proper function and prevent infiltration or disconnection.

Special populations requiring enhanced caution include geriatric horses, which may have reduced hepatic function affecting lidocaine metabolism even without overt liver disease. Debilitated or critically ill horses may be more susceptible to lidocaine effects and may have altered drug distribution due to changes in plasma proteins or body composition. Horses with pre-existing neurological conditions may be more difficult to monitor for toxicity signs, as baseline neurological abnormalities could mask early indicators. Very small horses and foals may require adjusted protocols, though lidocaine infusion is primarily used in adult horses undergoing abdominal surgery.

Competition and performance horse considerations are substantial for horses receiving lidocaine therapy. The medication is classified as prohibited under virtually all competition rules due to its analgesic and local anesthetic properties. Detection times following intravenous infusion can be prolonged, potentially requiring extended withdrawal periods before competition. Horses receiving lidocaine for surgical conditions will generally require significant recovery periods before returning to athletic activity regardless of drug testing considerations. Detailed treatment records should be maintained documenting all medications administered.

Administration precautions focus on ensuring accurate delivery of the intended dose. Infusion pump programming should be double-checked by qualified personnel. The concentration of lidocaine in the fluid bag must be accurately calculated and labeled. Tubing connections should be secure, and the catheter site should be monitored for infiltration. Having emergency drugs available, including diazepam for potential seizure management, is prudent when administering lidocaine infusions. Personnel should know how to recognize toxicity signs and how to respond appropriately.

Long-term use considerations are generally not relevant for lidocaine infusion, as treatment typically lasts two to four days for post-operative ileus management. Extended infusion beyond this period would warrant careful consideration of continued need versus risks. Prolonged infusion could theoretically increase the risk of cumulative toxicity or local effects at the catheter site. The goal is to use lidocaine for the minimum duration necessary to support return of gastrointestinal function, then discontinue the infusion.

Lidocaine injection solutions should be stored at controlled room temperature, typically between sixty-eight and seventy-seven degrees Fahrenheit, according to manufacturer specifications. The medication should be protected from light, which may cause degradation over time, though brief light exposure during preparation and administration is acceptable. Freezing should be avoided. Multi-dose vials should be handled according to established protocols for multi-dose containers, including appropriate cleaning of rubber stoppers before each entry and attention to beyond-use dating after first puncture. Single-dose vials should be used once and any remaining medication discarded.

Handling lidocaine in the clinical setting requires standard pharmaceutical precautions. Aseptic technique should be used when preparing infusion solutions to maintain sterility. The calculation of drug concentrations and infusion rates should be performed carefully and verified, as errors could result in significant under- or over-dosing. Prepared infusion solutions should be clearly labeled with the drug, concentration, date of preparation, and expiration time. Lidocaine solutions are generally stable for twenty-four hours or more when properly prepared, though facility protocols should be followed regarding maximum hang times for intravenous solutions.

Lidocaine does not pose unusual human exposure hazards during routine handling, though standard precautions should be observed. Significant skin exposure or accidental self-injection could produce local anesthetic effects. Hands should be washed after handling. The medication should be stored in appropriate locations away from patient care areas where it might be confused with other medications. Controlled access to lidocaine is advisable given its potential for human misuse, though it is not a controlled substance under federal regulations.

Disposal of unused or expired lidocaine should follow appropriate pharmaceutical waste guidelines. The medication should not be poured down drains or placed in regular trash. Partially used vials from single-dose preparations should be discarded in appropriate pharmaceutical waste containers. Facilities typically have protocols for managing pharmaceutical waste, and these should be followed. Sharps including needles and syringes used in preparation and administration require disposal in appropriate sharps containers.

Draft horse breeds requiring colic surgery present considerations related to their significantly larger body mass when calculating lidocaine infusion protocols. Accurate weight determination is essential for proper dosing, as draft horses may weigh eighteen hundred to twenty-two hundred pounds or more. The total amount of lidocaine required for appropriate dosing in a draft horse is substantially greater than for a light horse, requiring larger volumes of medication to be prepared and appropriate infusion pump settings. There is no evidence that draft breeds metabolize lidocaine differently than light horse breeds, so standard dosing rates per kilogram should apply once accurate weight is determined.

Light horse breeds and warmbloods represent the population in which most clinical experience with lidocaine infusion has been accumulated. Surgical colic cases in these breeds are common at equine referral centers, and standard lidocaine protocols have been developed based largely on experience with these populations. Individual variation in lidocaine sensitivity exists, and monitoring for toxicity signs should be performed regardless of breed. Thoroughbreds and other athletic breeds undergoing emergency colic surgery will require appropriate recovery time before returning to athletic activities, independent of medication considerations.

Ponies and miniature horses requiring colic surgery need careful attention to lidocaine dosing. The smaller body mass means that relatively small errors in concentration calculation or infusion rate could result in proportionally larger deviations from intended dosing. Precise measurement and calculation become particularly important. Additionally, smaller equines may be more difficult to monitor for subtle toxicity signs. Infusion pumps with appropriate accuracy for the lower flow rates required should be used.

Breed-specific genetic conditions may influence overall case management but do not specifically interact with lidocaine pharmacology. Friesians have higher rates of certain gastrointestinal conditions and may present for colic surgery, receiving standard lidocaine protocols. Quarter Horses with HYPP or other genetic conditions receiving lidocaine infusion should have their specific condition considered in overall management, though these conditions do not directly affect lidocaine use. Individual patient assessment incorporating breed background, concurrent conditions, and overall health status guides treatment decisions in each case.

Within the category of prokinetic agents used in equine surgical practice, lidocaine's unique mechanism and administration route distinguishes it from other options. Metoclopramide, a dopamine antagonist with prokinetic properties, may be used alongside or as an alternative to lidocaine in post-operative patients. Bethanechol, a direct cholinergic agonist, stimulates intestinal motility through muscarinic receptor activation. Erythromycin at low prokinetic doses activates motilin receptors to trigger migrating motor complexes. Cisapride, a serotonin receptor agonist available through compounding, provides yet another mechanism for enhancing motility. These agents work through different pathways than lidocaine and may be combined with it for synergistic effects in refractory cases.

Other medications commonly used alongside lidocaine in post-surgical colic patients address different therapeutic goals. Non-steroidal anti-inflammatory drugs such as flunixin meglumine or firocoxib provide analgesia and reduce inflammation. Antimicrobial therapy may be indicated depending on the nature of the surgical condition. Intravenous fluid therapy addresses dehydration and supports cardiovascular function. Gastric protectant medications may be used given the stress of surgery and potential for gastric ulceration. The overall treatment plan coordinates multiple medications to optimize patient outcomes.

Non-pharmacological approaches complement lidocaine therapy in managing post-operative ileus. Early mobilization, with hand-walking of horses as soon as safely possible following surgery, helps stimulate return of gut function. Gradual reintroduction of feed, typically starting with small amounts of grass hay, supports the transition to normal digestive function. Nasogastric intubation to decompress the stomach prevents gastric distension while motility remains impaired. Monitoring for complications such as incisional infection, adhesion formation, or recurrent obstruction is ongoing throughout recovery. The combination of appropriate pharmacological support and good nursing care maximizes the chances of successful recovery from colic surgery.